2.13
前日終値:
$2.11
開ける:
$2.13
24時間の取引高:
5.04M
Relative Volume:
0.54
時価総額:
$732.67M
収益:
$22,000
当期純損益:
$-190.89M
株価収益率:
-2.4534
EPS:
-0.8682
ネットキャッシュフロー:
$-149.63M
1週間 パフォーマンス:
-9.36%
1か月 パフォーマンス:
-4.05%
6か月 パフォーマンス:
+76.03%
1年 パフォーマンス:
+26.79%
Allogene Therapeutics Inc Stock (ALLO) Company Profile
名前
Allogene Therapeutics Inc
セクター
電話
(650) 457-2700
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics Inc
|
2.13 | 753.31M | 22,000 | -190.89M | -149.63M | -0.8682 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2026-04-10 | 再開されました | Jefferies | Buy |
| 2026-01-09 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-05-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 再開されました | Oppenheimer | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-06 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-08-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-28 | 繰り返されました | B. Riley Securities | Buy |
| 2021-10-20 | 開始されました | Cowen | Outperform |
| 2021-10-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-10-08 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 再開されました | Jefferies | Buy |
| 2021-05-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-14 | 開始されました | B. Riley Securities | Buy |
| 2021-01-26 | アップグレード | Stifel | Hold → Buy |
| 2020-12-10 | 再開されました | H.C. Wainwright | Buy |
| 2020-11-24 | 開始されました | BofA Securities | Buy |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-06-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-19 | アップグレード | ROTH Capital | Neutral → Buy |
| 2020-05-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-14 | ダウングレード | SunTrust | Buy → Hold |
| 2020-04-13 | 開始されました | SunTrust | Buy |
| 2020-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-24 | 開始されました | Berenberg | Hold |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-05 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Neutral |
| 2019-05-23 | 開始されました | Stifel | Hold |
| 2019-03-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Allogene Therapeutics Inc (ALLO) 最新ニュース
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
Allogene Therapeutics stock hits 52-week highhere's why - MSN
Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach - Traders Union
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Allogene licensor Cellectis faces patent lawsuit in the U.S. - MSN
JP Morgan Upgrades Allogene Therapeutics (ALLO) - MSN
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Allogene jumps on analysis of Phase 2 data for B-cell lymphoma asset cema-cel - MSN
Allogene Therapeutics Expands Cancer Trial into South Korea and Australia - HarianBasis.co
Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In - Yahoo Finance
10 Best Growth Stocks Under $10 to Invest In - Insider Monkey
Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach - Traders Union
Allogene Therapeutics announces public offering of $175M of common stock - MSN
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares - MarketBeat
[SCHEDULE 13G] Allogene Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares - Stock Titan
Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) - Insider Monkey
Allogene expands lymphoma trial to South Korea, Australia By Investing.com - Investing.com India
Allogene Therapeutics Inc (ALLO) News, Articles, Events & Latest Updates - Stocktwits
Allogene Therapeutics, Inc.Common Stock (NQ: ALLO - FinancialContent
Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026 - Stock Titan
Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening - Traders Union
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6%Should You Sell? - MarketBeat
Allogene Therapeutics (ALLO) Expands Groundbreaking Study in Sou - GuruFocus
Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia - marketscreener.com
Allogene expands lymphoma trial to South Korea, Australia - Investing.com
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
Allogene (NASDAQ: ALLO) proxy urges approval to raise authorized shares to 800M - Stock Titan
Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common Stock - Legal Desire Media and Insights
Allogene Therapeutics presents dual CAR-T cell data for high-risk myeloma after BCMA therapy - Traders Union
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - The Manila Times
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene raises $200.4 million in stock offering By Investing.com - Investing.com India
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - Sahm
ALLO Upgraded by JP Morgan -- Rating Changed to Neutral - GuruFocus
Allogene Therapeutics advances allogeneic CAR T interim results in early LBCL consolidation - Traders Union
ALLO Stock Rockets As ALPHA3 CAR‑T Data Reset Expectations - timothysykes.com
Allogene Therapeutics Inc (ALLO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):